BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Kineta Inc.

Headquarters: Seattle, WA, United States of America
Year Founded: 2008
Status: Public
Industry Sector: HealthTechnology
CEO: Shawn P. Iadonato, PhD
Number Of Employees: 5
Enterprise Value: $4,391,815
PE Ratio: -0.21
Exchange/Ticker 1: NASDAQ:KA
Exchange/Ticker 2: N/A
Latest Market Cap: $3,765,500

BioCentury | Jul 28, 2023
Deals

Biotech reverse mergers growing amid improving market conditions

Are 2023’s reverse mergers another sign of an improving biotech environment?
BioCentury | Jul 18, 2023
Management Tracks

Gosebruch named CEO of Neumora

Plus: Petti becomes CEO at Leucid Bio, and updates from Acelyrin, Larimar, Pharming and more
BioCentury | Jun 6, 2022
Deals

Sale of programs to J&J leaves Yumanity as shell for Kineta reverse merger

Combined company to advance Seattle biotech’s cancer programs as Yumanity’s eight-year history in neurodegeneration comes to a close
BioCentury | Feb 14, 2020
Targets & Mechanisms

Entrepreneur watch: Iwasaki targets the lymphatic system to clear brain tumors

After starting two companies this year, Yale’s Akiko Iwasaki clears glioblastoma in mice via brain lymphatics
BioCentury | Sep 27, 2017
Distillery Therapeutics

Infectious disease

BioCentury | Sep 8, 2017
Company News

Merck acquires cancer play Rigontec

BioCentury | Sep 6, 2017
Company News

Merck acquires cancer play Rigontec

BioCentury | Sep 6, 2017
Preclinical News

Human mAbs could treat Lassa fever

BioCentury | May 31, 2017
Distillery Therapeutics

Transplant

Items per page:
1 - 10 of 30